Evommune, Inc.
Business
Evommune is a clinical-stage biotechnology company developing therapies targeting chronic inflammatory diseases, with two lead candidates in Phase 2 development: EVO756, an oral MRGPRX2 antagonist for chronic spontaneous urticaria and atopic dermatitis, and EVO301, an IL-18 binding protein fusion for atopic dermatitis and ulcerative colitis. The company operates through drug discovery and clinical development programs advancing product candidates across multiple indications including migraine, asthma and other inflammatory conditions. Evommune generates revenue through sublicense agreements, including an exclusive deal with Maruho for EVO756 development in Japan.
Summary from 10-K filed 2026-07-01
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 |
|---|---|---|---|
| License revenue | 13 | 7 | |
| Total revenue | 13 | 7 | |
| Research and development | 74 | 64 | |
| General and administrative | 20 | 13 | |
| Total operating expenses | 94 | 77 | |
| Loss from operations | −81 | −70 | |
| Change in fair value of convertible preferred stock forward | 9 | — | |
| Interest income | 3 | 3 | |
| Other expense, net | −50,000 | −37,000 | |
| Total other income, net | 12 | 3 | |
| Net loss | −69 | −67 | |
| Deemed dividend | — | 2 | |
| Net loss attributable to common stockholders | −69 | −68 | |
| Basic net loss per share of common stock | −11.22 | −45.29 | |
| Diluted net loss per share of common stock | −11.22 | −45.29 | |
| Weighted average basic shares of common stock outstanding | 6 | 2 | |
| Weighted average diluted shares of common stock outstanding | 6 | 2 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | 44 | 16 | — | |
| Short-term investments | 105 | 56 | — | |
| Prepaid expenses and other current assets | 4 | 2 | — | |
| Total current assets | 153 | 74 | — | |
| Operating lease right-of-use assets, net | 1 | 472,000 | — | |
| Property and equipment, net | 994,000 | 1 | — | |
| Long-term investments | 67 | — | — | |
| Restricted cash | 1 | 208,000 | — | |
| Other non-current assets | 101,000 | 61,000 | — | |
| Total assets | 225 | 76 | — | |
| Accounts payable | 8 | 8 | — | |
| Accrued liabilities | 10 | 7 | — | |
| Operating lease liability, current portion | 242,000 | 487,000 | — | |
| Convertible preferred stock forward | — | 9 | — | |
| Deferred revenue | — | 3 | — | |
| Other current liabilities | 364,000 | 573,000 | — | |
| Total current liabilities | 18 | 28 | — | |
| Operating lease liability, non-current portion | 1 | — | — | |
| Financing lease liability | 181,000 | 535,000 | — | |
| Total liabilities | 19 | 29 | — | |
| Commitments and contingencies (Note 6) | — | — | — | |
| Convertible preferred stock: $0.0001 par value -10,000,000 and 157,657,729 shares authorized at December 31, 2025 and December 31, 2024, and 0 and 116,716,142 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively, (liquidation preference $0 and $210,328 at December 31, 2025 and December 31, 2024, respectively) | 0 | 192 | — | |
| Common stock, par value $0.0001 - 500,000,000 and 223,593,879 shares authorized at December 31, 2025 and December 31, 2024, respectively; 31,524,093 and 1,551,420 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | 3,000 | 0 | — | |
| Additional paid-in capital | 427 | 8 | — | |
| Accumulated deficit | −221 | −152 | — | |
| Total stockholders' equity (deficit) | 206 | −144 | −78 | |
| Total liabilities, convertible preferred stock, and stockholders' equity (deficit) | 225 | 76 | — |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 |
|---|---|---|---|
| Net loss | −69 | −67 | |
| Stock-based compensation expense | 6 | 2 | |
| Accretion of discount on investments | −2 | −2 | |
| Depreciation and amortization | 1 | 1 | |
| Prepaid expenses and other assets | −2 | −1 | |
| Accounts payable | −837,000 | 7 | |
| Accrued liabilities | 3 | 3 | |
| Operating lease liabilities | −730,000 | −769,000 | |
| Deferred revenue | −3 | — | |
| Net cash used in operating activities | −76 | −58 | |
| Purchases of investments | −199 | −90 | |
| Maturities of investments | 84 | 86 | |
| Purchase of property and equipment | −235,000 | −88,000 | |
| Net cash used in investing activities | −115 | −4 | |
| Proceeds from the sale of common stock in initial public offering, net of offering costs paid | 157 | — | |
| Proceeds from issuance of convertible preferred stock, net of issuance costs | 65 | 50 | |
| Proceeds from exercise of stock options | 6,000 | 13,000 | |
| Principal payments of finance lease liability | −400,000 | −200,000 | |
| Principal payments of financing obligation | −200,000 | −200,000 | |
| Taxes paid related to net share settlement of equity awards | −1 | — | |
| Net cash provided by financing activities | 221 | 49 | |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 29 | −13 | |
| Cash paid for interest | 7,000 | 34,000 | |
| Issuance of common stock upon conversion of convertible preferred stock | 257 | — | |
| Unpaid fixed asset purchases | 35,000 | — | |
| Vesting of early exercised stock options | 40,000 | 50,000 | |
| Assets acquired under finance leases | 10,000 | 1 | |
| Deferred offering costs in accounts payable | 294,000 | — | |
| Operating lease liabilities arising from obtaining right-of-use assets | 2 | — | |
| Deemed dividend from trigger of anti-dilution provision feature | — | 2 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Evommune, Inc.'s CIK number?
Evommune, Inc.'s SEC CIK number is 0002044725 (2044725). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Evommune, Inc.'s SEC filings?
All of Evommune, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Evommune, Inc. last report earnings?
Evommune, Inc. (EVMN) most recently filed an earnings 8-K with the SEC on May 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-211934). This is Evommune, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Evommune, Inc.'s most recent earnings 8-K?
Evommune, Inc.'s latest earnings 8-K (Item 2.02) was filed May 7, 2026 under accession 0001193125-26-211934. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Evommune, Inc.'s latest earnings 8-K →
Look up any company's CIK number →